Your browser doesn't support javascript.
loading
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
McGarry, Andrew; Rosanbalm, Shane; Leinonen, Mika; Olanow, C Warren; To, Dennis; Bell, Adam; Lee, Daniel; Chang, Jamie; Dubow, Jordan; Dhall, Rohit; Burdick, Daniel; Parashos, Sotirios; Feuerstein, Jeanne; Quinn, Joseph; Pahwa, Rajesh; Afshari, Mitra; Ramirez-Zamora, Aldolfo; Chou, Kelvin; Tarakad, Arjun; Luca, Corneliu; Klos, Kevin; Bordelon, Yvette; St Hiliare, Marie-Helene; Shprecher, David; Lee, Seulki; Dawson, Ted M; Roschke, Viktor; Kieburtz, Karl.
  • McGarry A; Cooper Medical School at Rowan University, Camden, NJ, USA; Clintrex Research Corporation, Sarasota, FL, USA. Electronic address: mcgarry-andrew@cooperhealth.edu.
  • Rosanbalm S; Rho, Hillsborough, NJ, USA.
  • Leinonen M; Clintrex Research Corporation, Sarasota, FL, USA.
  • Olanow CW; Clintrex Research Corporation, Sarasota, FL, USA.
  • To D; D&D Pharmatech - Neuraly, Gaithersburg, MD, USA.
  • Bell A; D&D Pharmatech - Neuraly, Gaithersburg, MD, USA.
  • Lee D; D&D Pharmatech - Neuraly, Gaithersburg, MD, USA.
  • Chang J; Rho, Hillsborough, NJ, USA.
  • Dubow J; Clintrex Research Corporation, Sarasota, FL, USA.
  • Dhall R; University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Burdick D; Booth Gardner Parkinson's Care Center, Kirkland, WA, USA.
  • Parashos S; Struthers Parkinson's Center, Minneapolis, MN, USA.
  • Feuerstein J; Neurosciences Center at UC Health University of Colorado Hospital, Aurora, CO, USA.
  • Quinn J; Oregon Health and Sciences University, Portland, OR, USA.
  • Pahwa R; University of Kansas Medical Center, Kansas City, KS, USA.
  • Afshari M; Rush University Medical Center, Chicago, IL, USA.
  • Ramirez-Zamora A; University of Florida College of Medicine, Gainesville, FL, USA.
  • Chou K; University of Michigan Medical Center, Ann Arbor, MI, USA.
  • Tarakad A; Baylor College of Medicine, Houston, TX, USA.
  • Luca C; University of Miami Health System, Miami, FL, USA.
  • Klos K; The Movement Disorder Clinic of Oklahoma, Tulsa, OK, USA.
  • Bordelon Y; University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA.
  • St Hiliare MH; Boston Medical Center, Boston, MA, USA.
  • Shprecher D; Banner Health, Sun City, AZ, USA.
  • Lee S; D&D Pharmatech - Neuraly, Gaithersburg, MD, USA.
  • Dawson TM; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Roschke V; D&D Pharmatech - Neuraly, Gaithersburg, MD, USA.
  • Kieburtz K; Clintrex Research Corporation, Sarasota, FL, USA.
Lancet Neurol ; 23(1): 37-45, 2024 01.
Article en En | MEDLINE | ID: mdl-38101901
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Exenatida / Agonistas Receptor de Péptidos Similares al Glucagón Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Exenatida / Agonistas Receptor de Péptidos Similares al Glucagón Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article